title: A comparison of the clinical outcomes of patients with invasive lobular carcinoma and invasive ductal carcinoma of the breast according to molecular subtype in a Korean population.
abstract: BACKGROUND
  To investigate the clinicopathological characteristics and the survival outcomes of invasive lobular carcinoma (ILC) patients compared to invasive ductal carcinoma (IDC) patients according to their molecular subtype.
  
  
  METHODS
  We compared the clinicopathological characteristics, breast cancer-specific survival (BCSS) and overall survival (OS) between patients with IDC (n = 14,547) and ILC (n = 528).
  
  
  RESULTS
  The ILC presented with a larger tumor size, more advanced cancer stage, increased rate of hormonal receptor positivity, human epidermal growth factor 2 (HER2) negativity and mastectomy than the IDC. The ILC patients more frequently presented with the luminal A subtype, whereas the IDC patients more frequently presented with the luminal B, HER2-overexpression, or triple negative subtype. The BCSS and OS were not significantly different between the IDC and ILC for each molecular subtype.
  
  
  CONCLUSIONS
  Similar to IDC patients, molecular subtype should be considered when determining the prognosis and treatment regimen for ILC patients.
authors.forename: Seung Taek
authors.initials: ST
authors.lastname: Lim
authors.forename: Jong Han
authors.initials: JH
authors.lastname: Yu
authors.forename: Heung Kyu
authors.initials: HK
authors.lastname: Park
authors.forename: Byung In
authors.initials: BI
authors.lastname: Moon
authors.forename: Byung Kyun
authors.initials: BK
authors.lastname: Ko
authors.affiliation: Department of Surgery, St, Vincent's Hospital, The Catholic University of Korea, 93, Joongboo-Daero Suwon, Paldal-gu, Kyunggi-do 442-723, Korea. yjsuh@catholic.ac.kr.
authors.forename: Young Jin
authors.initials: YJ
authors.lastname: Suh
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000453:epidemiology / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D018270:Carcinoma, Ductal, Breast / Q000453:epidemiology / Q000401:mortality / Q000556:secondary* / Q000628:therapy; D018275:Carcinoma, Lobular / Q000453:epidemiology / Q000401:mortality / Q000556:secondary* / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D056910:Republic of Korea / Q000453:epidemiology; D015996:Survival Rate; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone